motesanib + FOLFOX4

**motesanib + FOLFOX4** is an experimental combination therapy for metastatic colorectal cancer (mCRC) consisting of motesanib, an oral small-molecule inhibitor of several angiogenesis-related receptor tyrosine kinases (including VEGF receptors 1, 2, and 3, PDGF receptor, and Kit), plus the FOLFOX4 chemotherapy regimen, which includes folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. Motesanib works by inhibiting angiogenesis, thereby reducing tumor blood supply, while FOLFOX4 is a standard cytotoxic chemotherapy that injures rapidly dividing tumor cells. The combination was evaluated in early-phase clinical trials for safety and efficacy in patients with mCRC and demonstrated tolerability and modest clinical activity[1][3].\n- Motesanib was developed by Amgen and Takeda.\n- FOLFOX4, as a regimen, is not a commercial product but is composed of standard chemotherapeutics.